Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525714 | 0.90 | USP2 (0.46) | USP2SMN1; SMN2SCD5CYP11B2RECQL | |
| SCHEMBL156363 | 0.90 | USP2 (0.56) | USP2SMN1; SMN2SCD5GPR119RECQL | |
| SCHEMBL2960741 | 0.89 | USP2 (0.51) | USP2SMN1; SMN2SCD5CYP11B2GPR119 | |
| SCHEMBL1700547 | 0.87 | USP2 (0.53) | USP2SMN1; SMN2SCD5GPR119RECQL | |
| SCHEMBL1489016 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2SCD5GPR119RECQL | |
| SCHEMBL31751733 | 0.84 | USP2 (0.41) | USP2SMN1; SMN2SCD5CYP11B2GPR119 | |
| SCHEMBL1967958 | 0.84 | USP2 (0.50) | USP2SMN1; SMN2GPR119RECQLHPGD | |
| SCHEMBL27423987 | 0.83 | SMN1; SMN2 (0.58) | USP2SMN1; SMN2SCD5CYP11B2GPR119 | |
| SCHEMBL13452494 | 0.83 | SMN1; SMN2 (0.61) | USP2SMN1; SMN2SCD5CYP11B2RECQL | |
| SCHEMBL34464902 | 0.82 | USP2 (0.49) | USP2SMN1; SMN2SCD5CYP11B2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3806853-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | ONCO3R THERAPEUTICS BV (BE) | 2026-03-18 | — | — | EP | disclosed |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| WO-2025096637-A1 | SUBSTITUTED ARYL SULFONAMIDES FOR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2025-05-08 | — | — | WO | disclosed |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2025-04-01 | — | — | US | disclosed |
| CN-114667167-B | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20240228446-A1 | PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT | SHANGHAI JEMINCARE PHARMACEUTICAL CO., LTD (CN) | 2024-07-11 | — | — | US | disclosed |
| EP-4317139-A1 | PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20110201595-A1 | OXAZOLIDINYL ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-18 | — | — | US | disclosed |
| EP-2344485-A2 | OXAZOLIDINYL ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2011-07-20 | — | — | EP | disclosed |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | disclosed |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
| WO-2010041218-A2 | OXAZOLIDINYL ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-15 | — | — | WO | disclosed |
| EP-2144910-A2 | OXAZOLIDINONE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2009010299-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | disclosed |
| WO-2008126034-A2 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228446-A1 | PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT | ERG28, CYP51A1, DPM1 | USP2 4546/4885SMN1; SMN2 4449/4885SCD5 2776/4885 |
| US-20110201595-A1 | OXAZOLIDINYL ANTIBIOTICS | OXA1L, UBE2D3, PYM1 | USP2 1712/4885SMN1; SMN2 2942/4885SCD5 3163/4885 |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | TNF, IL1A, COL1A1 | USP2 4030/4885SMN1; SMN2 4676/4885SCD5 4324/4885 |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | USP2 3720/4885SMN1; SMN2 2461/4885SCD5 1617/4885 |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | USP2 3957/4885SMN1; SMN2 150/4885SCD5 724/4885 |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | OXA1L, XDH, UBE2D3 | USP2 3058/4885SMN1; SMN2 3353/4885SCD5 3921/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | USP2 3685/4885SMN1; SMN2 2897/4885SCD5 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.